Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis.
- Author:
Qiong-yu WANG
1
;
Hu-ling YAN
;
Ping LIU
;
Zhen-hui PENG
;
Sheng-shun TAN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Double-Blind Method; Down-Regulation; drug effects; genetics; Epidermis; drug effects; metabolism; pathology; Female; Gene Expression; drug effects; Humans; In Situ Hybridization; Keratolytic Agents; administration & dosage; therapeutic use; Male; Middle Aged; Neoplasm Proteins; genetics; Nicotinic Acids; administration & dosage; therapeutic use; Nuclear Proteins; genetics; Promyelocytic Leukemia Protein; Psoriasis; drug therapy; genetics; RNA, Messenger; biosynthesis; genetics; Transcription Factors; genetics; Tumor Suppressor Proteins; genetics
- From: Journal of Southern Medical University 2006;26(8):1146-1148
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the mechanism of tazarotene against active psoriasis vulgaris.
METHODSA randomized, controlled trial was conducted in 43 patients with active psoriasis vulgaris, who were divided into tazarotene and control groups. Promyelocytic leukemia (PML) mRNA in active psoriatic lesions before and 14 days after tazarotene treatment was detected by in situ hybridization.
RESULTSPML mRNA expression was detected not only in the basal layer (86.96%), but also in the suprabasal layers of the epidermis in the manner of focal expression (78.26%). After tazarotene treatment, virtually no PML mRNA expression could be detected in the psoriatic lesions (8.69% in the basal layer and 4.35% in the suprabasal layers). PML mRNA expression in the control group underwent no obvious changes during the observation.
CONCLUSIONSTazarotene may inhibit abnormal proliferation of keratinocytes through down-regulating PML gene expression in active psoriatic epidermis.
